Why carry out this study?

Adherence and persistence with treatment such as biologics are essential to control psoriasis (PsO)

Patient support programs (PSPs) may help in managing the disease and improving outcomes

We aimed to understand adherence and persistence to ixekizumab in Canadian patients with moderate-to-severe PsO who were enrolled in a PSP

What was learned from the study?

Ixekizumab-treated patients were highly adherent and persistent over 1 and 2 years of follow-up

A slightly higher proportion of biologic-naïve patients were adherent and persistent than biologic-experienced patients